Is VRTX overvalued right now?
A stock is overvalued when its market price sits above a reasonable fair value range. Use the live snapshot on this page for VRTX, then validate with fundamentals and peer multiples.
Vertex Pharmaceuticals Incorporated (VRTX) is currently Undervalued by 15.18%
Instant valuation answer
Vertex Pharmaceuticals Incorporated (VRTX) appears undervalued by approximately 15.18% based on our live valuation percent and intrinsic value estimate derived from DCF, P/E Multiple, and P/S Multiple models. Valuation can still differ across analyst models, growth expectations, and risk assumptions.
- Upside (live) 15.18% (from live valuation API)
- Confidence (live) 5/10 (Moderate)
Confidence Score is based on the magnitude of upside or downside vs intrinsic value.
Fair value estimate
Unlock fair valueCurrent price
$522.25
Stock valuation checker
Search our company database (same as the site header). Choose a result or type a ticker and press Check valuation.
Explore Our Valuation Calculators
Why is Vertex Pharmaceuticals Incorporated overvalued or undervalued?
Based on intrinsic value, Vertex Pharmaceuticals Incorporated (VRTX) looks priced ahead of a cash-flow-based fair value that blends growth, reinvestment needs, and a risk-adjusted discount rate.
Compared to historical valuation, today’s multiple exceeds the range implied by the company’s own five-year average—suggesting the market is more optimistic than its own past pricing of similar fundamentals.
Market expectations embedded in the price imply a demanding bar for execution: revenue cadence, margin stability, and capital returns would need to accelerate to justify a sustained premium versus fair value.
Key metrics
- P/E ratio
- 47.4x
- Revenue growth (TTM y/y)
- 20%
- Profit margin
- 40.7%
- Fair value (model)
- Unlock
Frequently asked questions — VRTX
What is Vertex Pharmaceuticals Incorporated's intrinsic value?
Our DCF, P/E Multiple, and P/S Multiple models estimate whether VRTX trades above or below fair value. At $522.25, Vertex Pharmaceuticals Incorporated currently looks undervalued on this snapshot. Tickerplace Pro unlocks the full dollar fair value estimate.
How is Vertex Pharmaceuticals Incorporated's intrinsic value calculated?
Tickerplace calculates VRTX's fair value using Discounted Cash Flow (DCF), P/E Multiple, and P/S Multiple models. We compare the resulting intrinsic value estimate to the live market price to flag undervalued or overvalued positioning.
Is VRTX undervalued right now?
Based on our 2026 valuation models, Vertex Pharmaceuticals Incorporated (VRTX) appears undervalued at $522.25 with about 15.2% upside to fair value. Treat this as a screen—verify fundamentals on the company profile.
Related companies — valuation
Peers for VRTX: open their overvalued / undervalued view.